Screener
Rhythm Pharmaceuticals, Inc. RYTM Total Cost of Revenue
Total Cost of Revenue at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The source filing: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-030549
| Line item | Three months ended March 31, 2026 | 2025 |
|---|---|---|
| License revenue | — | (5,014) |
| Total revenues | 60,112 | 32,704 |
| Costs and expenses: | ||
| Cost of sales | 7,157 | 3,648 |
| Research and development | 41,725 | 36,973 |
| Selling, general, and administrative | 63,591 | 39,087 |
| Total costs and expenses | 112,473 | 79,708 |
| Loss from operations | (52,361) | (47,004) |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Rhythm Pharmaceuticals, Inc.'s total cost of revenue?
- Rhythm Pharmaceuticals, Inc. (RYTM) reported total cost of revenue of $7.16M in Q1 2026.
- How has Rhythm Pharmaceuticals, Inc.'s total cost of revenue changed year-over-year?
- Rhythm Pharmaceuticals, Inc.'s total cost of revenue increased by 96.2% year-over-year, from $3.65M to $7.16M.
- What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s total cost of revenue?
- Over 4 years (2021 to 2025), Rhythm Pharmaceuticals, Inc.'s total cost of revenue has grown at a 138.8% compound annual growth rate (CAGR), from $599K to $19.49M.
- What does total cost of revenue mean?
- The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.
Ask your AI about Rhythm Pharmaceuticals, Inc.'s total cost of revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude